Johannes Schöneberg/Photo by Catherine Eng
The New Innovator Award will allow Schöneberg to understand how changes in the morphology and dynamics of the 4D mitochondrial network cause abnormalities in stem cell renewal. Breakthroughs in this area could contribute to the development of new therapies for cancer and bowel disorders. By opening this new window into mitochondrial biology, Schöneberg believes that new screening methods and treatment strategies can be developed that apply to the large number of diseases that are also linked to mitochondria, such as epilepsy, Parkinson’s and Alzheimer’s disease.
“The science advanced by these researchers is poised to open new avenues of discovery in human health,” said Acting NIH Director Lawrence A. Tabak. “This unique cohort of scientists will transform what is known in the biological and behavioral world. We are privileged to support this innovative science.
Established in 2007, the New Innovator Award, part of the NIH’s High-Risk, High-Reward Research Program, supports exceptionally innovative research conducted by scholars who are within 10 years of their final degree or residency. clinic and who have not yet received an NIH R01 or equivalent fellowship. In this program, researchers are encouraged to think beyond traditional boundaries and pursue innovative ideas in any area of research relevant to the NIH mission to advance knowledge and improve health. Each year, the Pooled Fund invites applications, conducts rigorous peer review of proposals, selects grantees, and oversees programs that pursue major scientific opportunities and gaps in the broader research enterprise that are of significant importance to the NIH.